Wednesday, August 21, 2019
Douglas Smith on a Shift in the Preemption Landscape
Douglas Smith (Kirkland & Ellis LLP) has posted to SSRN his article, A Shift in the Preemption Landscape?, Tenn. L. Rev. (forthcoming). Here is the abstract:
This article discusses the Supreme Court's recent decision in Merck, Sharp & Dohme v. Albrecht and its effect on the law of preemption. The Supreme Court held that judges, not juries, should decide preemption questions. It also issued a series of non-binding statements regarding the standards for preemption. This article discusses the Supreme Court decision and its potential effects on future cases.
August 21, 2019 in FDA, Preemption, Products Liability | Permalink | Comments (0)
Thursday, April 24, 2014
FDA to Regulate E-Cigarettes
The FDA announced its plans to begin regulating E-Cigarettes today. According to many consumers, the proposed regulations have taken too long already. For example, a March 23, 2014, New York Times article titled "Selling a Poison by the Barrel: Liquid Nicotine for E-Cigarettes," explained that,
These “e-liquids,” the key ingredients in e-cigarettes, are powerful neurotoxins. Tiny amounts, whether ingested or absorbed through the skin, can cause vomiting and seizures and even be lethal. A teaspoon of even highly diluted e-liquid can kill a small child.
As a USAToday article explains, even "[t]he proposed rules won't ban advertising unless the products make health-related claims nor will they ban the use of flavors such as chocolate or bubble gum, which public health officials say might attract children." Yet, the lawsuits so far have trended in the opposite direction of what one might expect. The most widely advertised lawsuits to date are either brought on behalf of smokers challenging New York City's ban on "vaping" e-cigarettes in public places or over e-cigarette patents.
April 24, 2014 in Current Affairs, FDA | Permalink | Comments (0) | TrackBack (0)
Wednesday, March 20, 2013
SCOTUS Oral Argument in Mutual Pharm. Co. v. Bartlett: Generic Pharmaceutical Manufacturers' Potential Immunity from Suit
Wall Street Journal article by Jess Bravin on Tuesday's argument, and more from SCOTUSblog.
March 20, 2013 in FDA, Pharmaceuticals - Misc., Products Liability | Permalink | Comments (0) | TrackBack (0)
Monday, January 21, 2013
Kelsey Larson and Carlos Lazatin on Crafting a Defense in Food-Labeling Class Actions
Corporate Counsel has a short piece, Crafting a Defense in Food-Labeling Class Actions, by O'Melveny's Kelsey Larson and Carlos Lazatin.
January 21, 2013 in Aggregate Litigation Procedures, Class Actions, FDA, Food and Drink, Procedure, Products Liability | Permalink | Comments (0) | TrackBack (0)
Sunday, January 29, 2012
PIP Breast Implants and Mass Torts in Europe
According to this article from CNN, French authorities have arrested Jean-Claude Mas, the founder of Poly Implant Protheses (PIP), in connection with alleged manslaughter and involuntary harm to a woman who died from cancer and had PIP breast implants. The article notes that 300,000 women in 65 countries received PIP breast implants, and that questions have been raised about the use of non-medical-grade silicon and PIP went bankrupt in late 2010.
The PIP breast-implants controversy may present an opportunity to observe non-U.S.-style mechanisms for what here would likely have been a mass tort litigation. Since the PIP breast implants were not permitted to be sold in the U.S., litigation may be concentrated abroad. In general, my sense is that the European approach is more reliant on criminal law than tort for deterrence, compensatory damages are limited because of the comparatively extensive governmental social insurance, punitive damages are unavailable, and class actions are traditionally not embraced (though class actions appear to be on the rise globally -- see, e.g., the Stanford Global Class Actions Exchange).
Interestingly, according to the article, one French woman who received PIP breast implants said, "Too bad we do not have a justice system like they do in the United States which allows the accumulation of penalties...because the small punishment he will receive for what he did to 300,000 to 400,000 women, is not much compared to what we have suffered because of him."
(H/t to my Mass Tort Litigation student Abigail Anderson for sending me the CNN story.)
January 29, 2012 in Aggregate Litigation Procedures, FDA, Foreign, Procedure, Products Liability | Permalink | Comments (0) | TrackBack (0)
Tuesday, December 13, 2011
Yaz Litigation Likely to Heat Up After FDA Relabeling
Last week the FDA voted 21-5 to revise the labeling on Yaz, Yasmin, Beyaz, Safyral, and its generic versions to clarify the potential risk of blood clots in the legs and lungs from taking the pills. After debating the conflicting data for more than nine hours, the panelists disagreed on the evidence's quality but agreed that the risks should be clearly stated in the label. Here's an excerpt from the Huffington Post's report:
"Clearly the wording is inadequate and incomplete," said Dr. Richard Bockman of New York's Hospital for Special Surgery. "Adverse events have to be made graphic so physicians and patients are aware of the consequences."
In an earlier vote, panelists voted 15-11 that the pills remain a beneficial option for preventing pregnancy. The majority ruling amounts to a vote of confidence for keeping the drugs on the market, though well over a third of panelists voted against the drug's overall benefit, citing numerous alternatives available.
"I can see no real group of patients that this drug benefited over existing alternatives," said Mark Woods of New York University School of Medicine. "Without any clear benefit, and given the potentially catastrophic risk, I voted no."
Two large studies conducted by German drugmaker Bayer have shown no difference in blood clots between patients taking the company's drugs and patients taking older medications.
But since 2009, five large studies have suggested drospirenone-containing pills carry a slightly higher risk of blood clots than older birth control pills, though events in both groups are very rare. Even a slightly higher risk can be critical because blood clots can trigger heart attacks, strokes and blockages in lungs or blood vessels.
Here's a link to a TIME magazine report and to a recent NY Times piece.
December 13, 2011 in FDA, Pharmaceuticals - Misc. | Permalink | Comments (0) | TrackBack (0)
Thursday, July 7, 2011
GMO Rice Lawsuits Settle for $750M
BNA Class Action Litigation Reporter reports that the lawsuits against Bayer Cropscience for the contamination of rice crops with genetically modified rice have settled. The case was In Re: Genetically Modified Rice Litigation, E.D. Mo., No. 4:06-md-1811.
The plaintiffs were denied class certification for predictable reasons. The settlement is equally predictably organized on the Vioxx model: it goes into effect if 85% of the farmers sign on.
For more information on the MDL GMO Rice Litigation see the E.D.Mo. website: http://www.moed.uscourts.gov/node/115. (As for this writing, not updated to reflect the BNA report of settlement). As the website notes, the GMO rice has since been de regulated by the FDA.
Image by scottchan.
July 7, 2011 in Aggregate Litigation Procedures, Environmental Torts, FDA, Settlement, Vioxx | Permalink | Comments (0) | TrackBack (0)
Thursday, March 25, 2010
Reynolds' Move Into Smokeless Products
Thorough article in the Wall Street Journal -- Smokeless Products Are Tough Test for Reynolds, by David Kesmodel.
March 25, 2010 in FDA, Regulation, Science, Tobacco | Permalink | Comments (0) | TrackBack (0)
Tuesday, March 16, 2010
Albany Law Journal Symposium Issue on Off-Label Drug Prescription
The Albany Law Journal of Science & Technology has published a symposium issue on Regulating the Cure: Topics Arising Out of the Prescription of Drugs Off-Label. My article, Promotion of Off-Label Drug Use: In Favor of a Regulatory Retreat, 19 Alb. L.J. Sci & Tec. 609 (2009), is included.
March 16, 2010 in Aggregate Litigation Procedures, FDA, Mass Tort Scholarship, Off-Label Drug Use, Pharmaceuticals - Misc., Procedure, Products Liability, Regulation, Resources - Federal Agencies, Science | Permalink | Comments (0) | TrackBack (0)
Friday, December 11, 2009
GAO Says FDA Hasn't Made Enough Safety Reforms
The AP has the story here. While the FDA has made some changes, it has not transferred authority to the Office of Surveillance and Epidemiology. H/T Torts Prof Blog.
December 11, 2009 in FDA | Permalink | Comments (0) | TrackBack (0)
Thursday, October 29, 2009
WLF Web Seminar on Off-Label Communication
On October 14, 2009, the Washington Legal Foundation hosted a web seminar, Communicating on Off-Label Treatments: Navigating the Treacherous Path Paved by Civil and Criminal Law Enforcement, with speakers Robert Salerno and Adam Hoffinger of Morrison & Foerster. Streaming video of the event is available online.
October 29, 2009 in FDA, Off-Label Drug Use, Pharmaceuticals - Misc., Procedure, Regulation, Resources - Federal Agencies, Resources - Organizations, Science | Permalink | Comments (0) | TrackBack (0)
Tuesday, October 20, 2009
Fall 2009 Newsletter for ABA Mass Torts Litigation Committee
The newsletter is now available and includes articles on Lone Pine orders, public nuisance law, federal preemption, sophisticated user and sophisticated intermediary defenses, the Fake Bad Scale Test, and document review.
October 20, 2009 in FDA, Mass Tort Scholarship, Medical Devices - Misc., Preemption, Procedure, Products Liability, Regulation | Permalink | Comments (0) | TrackBack (0)
Friday, September 18, 2009
The FDA recently sent a warning letter to Bayer, which manufacturers Yaz and Yasmin (both types of birth control pills), that it has quality control problems at its German plant. The FDA claims that Bayer's testing method averaged out the test results as opposed to reporting results for each batch. Bayer had the batches shipped to the U.S. between 2007 and 2009.
This news is simply the most recent concern about Yaz. Litigation is already pending in Pennsylvania in front of Judge Sandra Mazer Moss of the Philadelphia Court of Common Pleas, alleging that the drug causes severe side effects including blood clots, strokes, heart attacks, gallbladder disease, deep vein thrombosis, pulmonary embolisms and even sudden death. There has been some speculation around the internet that the FDA will recall the drug. As the U.S. Recall News reports:
"In July 24, 2009, a petition was filed to consolidate the many lawsuits against Bayer over Yaz and Yasmin into a multidistrict litigation (MDL). There is a hearing scheduled for September 24, 2009 to decide whether or not they will be consolidated."
"Andrew Gillin, an attorney handling several California Yaz lawsuits says the litigation is still in the early stages. “A petition has been filed to combine all of the federal lawsuits into a multi-district litigation (MDL) case. Later this month, a panel of federal judges will determine whether the cases involve sufficiently common questions of fact, and whether or not to consolidate,” explained Mr. Gillin."
September 18, 2009 in FDA, Pharmaceuticals - Misc. | Permalink | Comments (0) | TrackBack (0)
Wednesday, September 2, 2009
Tobacco Companies Bring First Amendment Challenge to New Marketing Rules
September 2, 2009 in FDA, Tobacco | Permalink | Comments (0) | TrackBack (0)
Monday, August 31, 2009
Bill Marler on Legal Issues for Food Safety
Bill Marler has posted his brief article, Legal Issues for Food Safety, on Marler Blog.
August 31, 2009 in E Coli, FDA, Food and Drink, Food Poisoning | Permalink | Comments (0) | TrackBack (0)
Monday, August 24, 2009
Richard Epstein on Consumer Regulation
In his July 14 Forbes column, Vanguard or Rearguard?, Richard Epstein (Chicago & NYU) recounts the history of the FDA, as well as other regulatory frameworks, and concludes that "[r]egulatory failure is, on average, a far greater risk than market failure."
August 24, 2009 in FDA, Mass Tort Scholarship, Pharmaceuticals - Misc., Products Liability | Permalink | Comments (0) | TrackBack (0)
Tuesday, August 18, 2009
First Circuit Decision on Federal Claims Act
FDA Law Blog analyzes the decision in United States ex rel Duxbury v. Ortho Biotech Products.
August 18, 2009 in FDA, Pharmaceuticals - Misc., Procedure, Products Liability | Permalink | Comments (0) | TrackBack (0)
Saturday, August 15, 2009
Richard Epstein on Preemption and the Medical Device Safety Act
Richard Epstein (Chicago & NYU) discusses them both in his recent Forbes column.
August 15, 2009 in FDA, Mass Tort Scholarship, Pharmaceuticals - Misc., Preemption | Permalink | Comments (0) | TrackBack (0)
Friday, August 14, 2009
Third Circuit Rejects FDA Preemption for Snapple Consumer Fraud Suit
More from Allison Frankel's short article in Am Law Daily. Here's the opinion.
August 14, 2009 in Aggregate Litigation Procedures, Class Actions, FDA, Food and Drink, Preemption, Procedure | Permalink | Comments (0) | TrackBack (0)
Wednesday, August 12, 2009
Jason C. Miller on Michigan's Regulatory Compliance Defense
Jason C. Miller of University of Michigan has posted to SSRN his Note, When and How to Defer to the FDA: Learning from Michigan's Regulatory Compliance Defense, 15 Mich. Telecomm. & Tech. L. Rev. 565 (2009). Here's the abstract:
Should FDA approval of a drug affect products liability litigation? This remains one of the most debated questions in the law. Although the Supreme Court recently held that state tort law is not forced to defer to the FDA's finding that a drug is safe through preemption, states remain free to defer to the FDA by providing a regulatory compliance defense in state substantive law. Michigan made exactly such a choice in enacting the only complete defense for FDA-approved drugs. Compliance with FDA regulations conclusively establishes a lack of products liability under Michigan law. With preemption seemingly off the table after Wyeth v. Levine, advocates of greater deference to the FDA may use Michigan as a model for legislation in other states. Much can be learned from examining Michigan's law.
Michigan's regulatory compliance defense properly recognizes that an FDA-approved drug carrying an FDA-approved label should not be considered defective. However, the statute's absolute immunity provides no compensation for injured parties in any circumstance, including situations where the FDA process has failed to protect consumers. This Note examines the question of FDA approval in state tort actions, discusses Michigan's answer to that question, and offers a proposal that would block most private actions against FDA-approved drugs (as Michigan has done), but would allow a state attorney general to bring suits in certain circumstances. The state attorney general model detailed in this Note stakes out a middle ground in the debate over the significance of FDA approval. The proposal recognizes the primacy of the FDA, but also recognizes the need for a back-up that can provide deterrence and compensation in the few cases that slip through the FDA's regulatory cracks.
August 12, 2009 in FDA, Mass Tort Scholarship, Preemption, Products Liability | Permalink | Comments (0) | TrackBack (0)